Verastem Given Consensus Rating of “Buy” by Analysts (NASDAQ:VSTM)
Verastem (NASDAQ:VSTM) has earned an average rating of “Buy” from the seven brokerages that are presently covering the stock, ARN reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $19.14.
A number of analysts have recently weighed in on VSTM shares. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Verastem in a research note on Friday. They now have a $14.00 price target on the stock. Separately, analysts at Oppenheimer initiated coverage on shares of Verastem in a research note on Monday, July 7th. They set a “market perform” rating and a $8.99 price target on the stock.
Verastem (NASDAQ:VSTM) opened at 8.64 on Tuesday. Verastem has a one year low of $7.10 and a one year high of $17.30. The stock has a 50-day moving average of $9.36 and a 200-day moving average of $11.04. The company’s market cap is $223.2 million.
Verastem (NASDAQ:VSTM) last announced its earnings results on Thursday, May 8th. The company reported ($0.51) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.43) by $0.08. On average, analysts predict that Verastem will post $-2.06 earnings per share for the current fiscal year.
Verastem, Inc is a United States-based biopharmaceutical company. The Company focuses on discovering and developing drugs to treat cancer by targeting cancer stem cells, which are an underlying cause of tumor recurrence and metastasis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.